The company's freeze-dried human rabies vaccine (human diploid cells) uses human diploid cells that are widely used in vaccine production internationally. The cells are derived from healthy human embryonic lung tissue, without any residual heterologous cells, and without any potential risks such as the introduction of heterologous proteins and DNA. The vaccine has the advantages of good immunogenicity, fast onset, good safety, and long duration of immunity, which is suitable for people with allergic constitutions, the elderly, children and other people with low immunity. During the reporting period, freeze-dried human rabies vaccine (human diploid cells) was carrying out sample preparation for Phase I clinical trials.